Sensitizing tumor cells to radiotherapy

March 1, 2012

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. Tumor resistance to radio- and/or chemotherapy remains a significant clinical problem.

A team of researchers led by Nils Cordes, at Dresden University of Technology, Germany, has now identified a way to enhance the sensitivity of human HNSCC cell lines to radiation such that their growth is delayed in xenografted mice.

In the study, Cordes and colleagues determined that a beta-1 integrin/FAK/cortactin signaling pathway is crucial for HNSCC resistance to radiotherapy. Inhibiting beta-1 integrin sensitized HNSCC cells to radiotherapy and delayed in xenografted mice. Thus, Cordes and colleagues suggest that targeting beta-1 integrin could be used in combination with radiotherapy and radiochemotherapy to increase the survival of patients with HNSCC.

Explore further: PXR: A stepping stone from environmental chemical to cancer?

More information: Beta-1 integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy, Journal of Clinical Investigation.

Related Stories

PXR: A stepping stone from environmental chemical to cancer?

July 11, 2011

Several chemicals that can accumulate to high levels in our body (for example BPA and some pesticides) have been recently linked to an increased risk of cancer and/or impaired responsiveness to anticancer drugs. A team of ...

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.